Dear Doctor Letter (Rote-Hand-Brief) on Thalidomide Celgene™ (thalidomide): Risk of second primary haematological malignancies
2013.04.08
Active substance: thalidomide
The pharmaceutical manufacturer is sending out information on the risk of second primary haematological malignancies in patients treated with thalidomide.
Updated
(SPC) with highlighted changes.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN